FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597149898> ?p ?o ?g. }

• W2597149898 abstract "6002 Background: Sym004 is a first-in-class drug mixture of two mAbs targeting non-overlapping epitopes on the EGFR. In preclinical models, Sym004 exhibited more pronounced EGFR internalization, degradation and tumor growth inhibition than cetuximab. Sym004 was investigated as monotherapy in palliative squamous cell carcinoma of the head and neck (SCCHN) patients (pts). Methods: SCCHN pts progressing after anti-EGFR mAbs for palliation were eligible. Documented clinical benefit (PR, CR or SD for at least 8 weeks according to RECIST) on an anti-EGFR mAb-containing regimen followed by disease progression during or within 12 weeks after treatment cessation was required. The primary endpoint of this multicentre single arm trial was centrally evaluated progression-free survival (PFS), estimated by median PFS and 24 week progression free rate. Secondary endpoints included objective tumor response, safety, biomarkers and pharmacokinetics. Pts received weekly iv infusions of 12 mg/kg Sym004 until disease progression. Tumor evaluation was performed week 6, 12 and every 8 weeks thereafter. Results: Based on the statistical hypothesis, 26 pts were included, of whom 23 had progressed while on anti-EGFR mAb treatment. One of 19 evaluable pts was HPV positive and no EGFRvIII mutation was detected in 21 evaluable pts. No anti-drug antibodies were detected. Independent central review of CT/MRI scans from 20 evaluable pts showed tumor shrinkage in 8 pts (% decrease in sum of the largest diameters: 6.5, 7.1, 9.6, 10.2, 11.3, 13.6, 16.7, 27.1) and 14 pts had SD as best overall response. Median PFS was 82 days (95% CI: 41, 140) and 24 week progression free rate was 12% (95% CI: 1, 39). During treatment 25/26 (96%) pts developed skin rash with ≥ grade 3 reported in 11/26 (42%) pts. Hypomagnesemia ≥ grade 3 was reported in 10/26 (38%) pts. Sym004 treatment resulted in a marked down regulation of EGFR in centrally reviewed biopsies from skin and tumors. Conclusions: Sym004 demonstrated clinical activity in heavily pretreated, predominately HPV negative pts with advanced SCCHN previously progressing on or after anti-EGFR mAbs. No unexpected toxicities were reported. Clinical trial information: NCT01417936." @default.
• W2597149898 created "2017-03-23" @default.
• W2597149898 creator A5001462136 @default.
• W2597149898 creator A5011885579 @default.
• W2597149898 creator A5013825576 @default.
• W2597149898 creator A5026322585 @default.
• W2597149898 creator A5041435375 @default.
• W2597149898 creator A5044089291 @default.
• W2597149898 creator A5047006205 @default.
• W2597149898 creator A5057110201 @default.
• W2597149898 creator A5062966348 @default.
• W2597149898 creator A5066640097 @default.
• W2597149898 creator A5066800365 @default.
• W2597149898 creator A5068158443 @default.
• W2597149898 creator A5088397986 @default.
• W2597149898 date "2013-05-20" @default.
• W2597149898 modified "2023-10-04" @default.
• W2597149898 title "Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study." @default.
• W2597149898 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.6002" @default.
• W2597149898 hasPublicationYear "2013" @default.
• W2597149898 type Work @default.
• W2597149898 sameAs 2597149898 @default.
• W2597149898 citedByCount "6" @default.
• W2597149898 countsByYear W25971498982013 @default.
• W2597149898 countsByYear W25971498982014 @default.
• W2597149898 countsByYear W25971498982015 @default.
• W2597149898 countsByYear W25971498982016 @default.
• W2597149898 countsByYear W25971498982017 @default.
• W2597149898 crossrefType "journal-article" @default.
• W2597149898 hasAuthorship W2597149898A5001462136 @default.
• W2597149898 hasAuthorship W2597149898A5011885579 @default.
• W2597149898 hasAuthorship W2597149898A5013825576 @default.
• W2597149898 hasAuthorship W2597149898A5026322585 @default.
• W2597149898 hasAuthorship W2597149898A5041435375 @default.
• W2597149898 hasAuthorship W2597149898A5044089291 @default.
• W2597149898 hasAuthorship W2597149898A5047006205 @default.
• W2597149898 hasAuthorship W2597149898A5057110201 @default.
• W2597149898 hasAuthorship W2597149898A5062966348 @default.
• W2597149898 hasAuthorship W2597149898A5066640097 @default.
• W2597149898 hasAuthorship W2597149898A5066800365 @default.
• W2597149898 hasAuthorship W2597149898A5068158443 @default.
• W2597149898 hasAuthorship W2597149898A5088397986 @default.
• W2597149898 hasConcept C126322002 @default.
• W2597149898 hasConcept C143998085 @default.
• W2597149898 hasConcept C159654299 @default.
• W2597149898 hasConcept C203014093 @default.
• W2597149898 hasConcept C203092338 @default.
• W2597149898 hasConcept C2776694085 @default.
• W2597149898 hasConcept C2778822529 @default.
• W2597149898 hasConcept C2779998722 @default.
• W2597149898 hasConcept C2780739268 @default.
• W2597149898 hasConcept C2781413609 @default.
• W2597149898 hasConcept C535046627 @default.
• W2597149898 hasConcept C542903549 @default.
• W2597149898 hasConcept C71924100 @default.
• W2597149898 hasConceptScore W2597149898C126322002 @default.
• W2597149898 hasConceptScore W2597149898C143998085 @default.
• W2597149898 hasConceptScore W2597149898C159654299 @default.
• W2597149898 hasConceptScore W2597149898C203014093 @default.
• W2597149898 hasConceptScore W2597149898C203092338 @default.
• W2597149898 hasConceptScore W2597149898C2776694085 @default.
• W2597149898 hasConceptScore W2597149898C2778822529 @default.
• W2597149898 hasConceptScore W2597149898C2779998722 @default.
• W2597149898 hasConceptScore W2597149898C2780739268 @default.
• W2597149898 hasConceptScore W2597149898C2781413609 @default.
• W2597149898 hasConceptScore W2597149898C535046627 @default.
• W2597149898 hasConceptScore W2597149898C542903549 @default.
• W2597149898 hasConceptScore W2597149898C71924100 @default.
• W2597149898 hasLocation W25971498981 @default.
• W2597149898 hasOpenAccess W2597149898 @default.
• W2597149898 hasPrimaryLocation W25971498981 @default.
• W2597149898 hasRelatedWork W1963973664 @default.
• W2597149898 hasRelatedWork W2126488520 @default.
• W2597149898 hasRelatedWork W2598983139 @default.
• W2597149898 hasRelatedWork W2729289325 @default.
• W2597149898 hasRelatedWork W2794605011 @default.
• W2597149898 hasRelatedWork W2901178367 @default.
• W2597149898 hasRelatedWork W3127911026 @default.
• W2597149898 hasRelatedWork W3164367827 @default.
• W2597149898 hasRelatedWork W3165165741 @default.
• W2597149898 hasRelatedWork W4310754871 @default.
• W2597149898 isParatext "false" @default.
• W2597149898 isRetracted "false" @default.
• W2597149898 magId "2597149898" @default.
• W2597149898 workType "article" @default.